EU/3/06/410

Table of contents

About

On 27 October 2006, orphan designation (EU/3/06/410) was granted by the European Commission to GP-Pharm S.A., Spain, for doxorubicin hydrochloride (liposomal) for the treatment of soft tissue sarcoma.

Key facts

Active substance
Doxorubicin hydrochloride (liposomal)
Disease / condition
Treatment of soft tissue sarcoma
Date of decision
27/10/2006
Outcome
Positive
Orphan decision number
EU/3/06/410

Sponsor's contact details

GP-Pharm S.A.
Pol. Ind. Els Vinyets els Fogars 2
Carretera Comarcal 244, km 22
08777 St Quintí de Mediona
Barcelona
Spain
Telephone: +34 93 819 22 00
Telefax: +34 93 638 93 93

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Ligue Nationale Contre le Cancer
    14 Rue Corvisart
    75013 Paris
    France
    Telephone: +33 1 53 55 24 00
    Telefax: +33 1 43 36 91 10
    E-mail: ligue@ligue-cancer.net
  • Deutsche Krebshilfe e. V.
    Buschstr. 32
    53113 Bonn
    Germany
    Telephone: +49 2 287 29 900
    Telefax: +49 2 287 29 90 11
    E-mail: deutsche@krebshilfe.de
  • Macmillan Cancer Support (merged with CancerBACUP)
    3 Bath Place
    Rivington Street
    London EC2A 3JR
    United Kingdom
    Telephone: +44 20 7696 9003
    Switchboard open during office hours, Mon–Fri, 09:00 – 12:00 and 14:00 –16:45.
    Telefax: +44 20 7696 9002

How useful was this page?

Add your rating